-

KARL STORZ Awarded Defense Logistics Agency Contract Competitive Multiyear Contract Covers Patient Monitoring and Capital Equipment

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ Endoscopy-America, Inc., a leader in minimally invasive surgical technology and related medical systems, has been awarded a major contract by the Defense Logistics Agency (DLA) under the Patient Monitoring and Capital Equipment (PMCE) solicitation SPE2D1-17-R-0001. With a maximum award value of $450M, this contract has a five-year base period with an option for five more, negotiated in one-year increments. This is an Indefinite-Delivery Indefinite-Quantity (IDIQ) contract that can be used by all branches of the federal government, including the Army, Air Force, Navy, Marines, Coast Guard, and Veterans Health Administration as well as other agencies utilizing federally allocated dollars.

“We are honored to support the DLA Troop Support Medical Supply in establishing the next generation of the Patient Monitoring and Capital Equipment program,” said Patrick Neely, Director of Federal Healthcare at KARL STORZ. “With expertise ranging from emergency intubation monitors to completely integrated surgical environments, we’re well positioned to help the DLA deliver top-notch treatment to military personnel and their families, across all sites of care.”

KARL STORZ Endoscopy-America, Inc., is an affiliate of KARL STORZ SE & Co. KG, an international leader for 75 years in advanced medical technology, providing surgical and procedural imaging, instrumentation, and enterprise-wide integration. Based in Tuttlingen, Germany, KARL STORZ SE & Co. KG is a family-owned company that designs, engineers, manufactures, and markets all its products with an emphasis on visionary design, precision craftsmanship, and clinical effectiveness. For more information, call (800) 421-0837 or visit the company’s website at www.karlstorz.com.

Contacts

Susan Jaffy Marx
Marketing Communications
KARL STORZ Endoscopy-America, Inc.
(424) 218-8701

KARL STORZ Endoscopy-America, Inc.


Release Versions

Contacts

Susan Jaffy Marx
Marketing Communications
KARL STORZ Endoscopy-America, Inc.
(424) 218-8701

More News From KARL STORZ Endoscopy-America, Inc.

ADDING MULTIMEDIA KARL STORZ Announces FDA Clearance for ENDOFLATOR + Insufflator and Smoke Evacuation System

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clearance for the ENDOFLATOR™ +. ENDOFLATOR + is the next-generation insufflator with integrated surgical smoke evacuation system designed to meet the evolving needs of modern operating rooms. Using carbon dioxide gas, an insufflator establishes and maintains a stable working cavity within the body during laparos...

KARL STORZ Unifies Canada, US, and Veterinary Organizations to Form North America Region Led by Sonal Matai

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ, a family-owned medical technology company headquartered in Tuttlingen, Germany, today announced the creation of a North America region that unifies its US, Canada, and Veterinary businesses under the leadership of Sonal Matai. Matai joined KARL STORZ in 2022 and was appointed to lead KARL STORZ United States in early 2024. As President of North America, Matai will now oversee key functions such as commercial operations, research and development,...

AventaMed, a KARL STORZ Company, Receives Expanded Indication for Solo+ Tympanostomy Tube Device (TTD)

EL SEGUNDO, Calif.--(BUSINESS WIRE)--KARL STORZ United States is proud to announce that the US Food and Drug Administration (FDA) has cleared an expanded indication for the AventaMed Solo+™ Tympanostomy Tube Device (TTD), allowing its use in pediatric patients aged 6 months and older. This expanded clearance builds on the previous 510(k) clearance, which was indicated for patients 6 to 24 months old. The Solo+ device represents a significant advancement in pediatric ENT care. It is intended to...
Back to Newsroom